Pulling SEC filings + quote and writing the call…

Lifevantage Corp
Next earnings Sep 2, 2026 (after close) · consensus $0.13 EPS, $46.9M rev
Last earnings +9.3% on 2026-05-06
Debt-free, cash-generative nutraceutical at 8x earnings after a breakout FY25 — cheap enough to own despite the fragile MLM model.
P/E (price / FY diluted EPS) 8.3 · FY2025 / current price
Quality fundamentals and an attractive price line up (~358% below fair value) — the rarer case where both the business and the entry look good.
LFVN just printed its best year in half a decade: FY2025 revenue of $229M (+14.2%) reversed the 2021–2024 stagnation ($220M→$206M→$213M→$200M), and net income leapt to $9.80M (+233.8%) on operating income of $12.2M (+181.6%). The economics underneath are genuinely attractive — 80.4% gross margin, 28.3% ROE, $11.9M operating cash flow against just $1.37M capex (~$10.5M free cash flow), $20.2M cash and effectively no debt (last reported long-term and current debt both $0; only an undrawn $5.0M line). At $6.20 the stock trades at 8.3x diluted EPS of $0.75, 0.3x sales, and a low-teens FCF yield. For a profitable, self-funding business returning cash via dividends and buybacks, that is a cheap absolute multiple.
The catch is what kind of business it is. LFVN is a direct-selling (MLM) operation whose revenue is only as durable as its independent-consultant base, and the 10-K is unusually candid: it has 'experienced discord among our leading independent consultants,' warns that the departure of a single leader 'can be a major disruption,' and flags ongoing legal proceedings with former consultants plus broad regulatory exposure. The five-year revenue line — flat-to-down for four years before this year's pop — shows exactly how fragile the top line is, and net income has swung from $12.9M (FY21) to ~$2.5–3M (FY22–24) and back to $9.80M. One strong year does not establish a trend, and the deeply negative retained earnings (-$104M) reflect a history of returning more cash than the franchise has durably earned.
Is LFVN a buy? The one-page verdict, explained →
BUY verdict with defined risk: the short call finances part of the long one; max loss is the net debit.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $220M | $206M | $213M | $200M | $229M |
| Gross profit | $182M | $168M | $170M | $159M | $184M |
| Operating income | $17.6M | $7.58M | $4.26M | $4.33M | $12.2M |
| Net income | $12.9M | $3.12M | $2.54M | $2.94M | $9.80M |
| Diluted EPS | $0.90 | $0.24 | $0.20 | $0.23 | $0.75 |
| Net margin | 5.9% | 1.5% | 1.2% | 1.5% | 4.3% |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Q3 FY26 quarterly report (period 2026-03-31) filed
Q3 FY26 quarterly report (period 2026-03-31) filed
Officer/director change (Item 5.02); leadership transition disclosed
Refiled $75M shelf registration; preserves capital access, possible dilution
Q2 FY26 quarterly report filed
Q2 FY26 quarterly report filed
Officer/director departure or appointment (Item 5.02)
Annual meeting voting results disclosed (Item 5.07)
Q1 FY26 quarterly report filed
Sources: SEC EDGAR (CIK 0000849146, latest 10-Q filed 2026-05-06) · EODHD · Proprietary analysis · as of 6/30/2026, 12:29:51 PM.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 30, 2026, 8:29 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Last 90 days: 1 open-market buy · 1 sale
| 2026-06-15 | Lewis Darwin Director | Buy | 705.00 @ $8.60 | $6.06K |
| 2026-06-03 | BEINDORFF MICHAEL A Director | Sell | 10.0K @ $8.55 | $85.5K |
| 2026-04-01 | Neufeld Alissa General Counsel | Tax | 1.45K @ $4.20 | $6.07K |
| 2026-04-01 | Fife Steven R President and CEO | Tax | 8.18K @ $4.20 | $34.4K |
| 2026-04-01 | Aure Carl Chief Financial Officer | Tax | 1.53K @ $4.20 | $6.41K |
| 2026-04-01 | Cunningham Kristen Chief Sales Officer | Tax | 1.93K @ $4.20 | $8.10K |
| 2026-03-16 | Lewis Darwin Director | Buy | 1.05K @ $5.23 | $5.52K |
| 2026-03-02 | Dayton Judd Director | Buy | 10.5K @ $4.53 | $47.6K |
| 2026-02-27 | Dayton Judd Director | Buy | 18.1K @ $4.63 | $83.8K |
| 2026-02-26 | Dayton Judd Director | Buy | 4.60K @ $4.58 | $21.1K |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
1195 tracked peers · median